Product Images Sacubitril And Valsartan

This is a description of a prescription medication called Sacubitril and Valsartan in the form of film-coated tablets. Each tablet contains 24 mg of sacubitril and 26 mg of valsartan. The usual dosage should be followed as per prescribing information. It should be stored at 25°C with excursions between 15-30°C. It is advised to protect the tablets from moisture and keep them out of reach of children. The medication is manufactured by MSN Laboratories in India and distributed by Novadoz Pharmaceuticals in the USA. The tablets are available in a pack containing 180 tablets.*

This text provides important details about Sacubitril and Valsartan Tablets, 24 mg/26 mg. The tablets contain a combination of sacubitril and valsartan and come in a pack of 60 tablets. It specifies the usual dosage and storage conditions, stating that the tablets should be stored at 25°C with excursions permitted between 15-30°C and protected from moisture. The manufacturing details are also provided, indicating that they are manufactured by MSN Laboratories Private Limited in India and distributed by Novadoz Pharmaceuticals LLC in the United States. The contact information for Novadoz Pharmaceuticals LLC is also given.*

This is a description of Sacubitril and Valsartan tablets with a strength of 49 mg/51 mg, containing 180 tablets in the package. The tablets are film-coated and the usual dosage is mentioned in the prescribing information. The storage conditions are recommended to be at 25°C with excursions between 15°C to 30°C. The manufacturer is MSN Laboratories Private Limited in India, and the distributor is Novadoz Pharmaceuticals LLC based in Piscataway, NJ. It is vital to protect the tablets from moisture and keep them out of the reach of children. The tablets are available by prescription only.*

Each film-coated tablet contains 49 mg of sacubitril and 51 mg of valsartan. The usual dosage information must be obtained through prescribing information. It is recommended to store the tablets at room temperature between 59°F to 86°F and to protect them from moisture. These tablets should be kept out of reach of children. The product is manufactured by MSN Laboratories Private Limited in Telangana, India, and distributed by Novadoz Pharmaceuticals LLC in Piscataway, New Jersey, USA.*

This text contains information about a medication called Sacubitril and Valsartan Tablets. Each tablet contains 97 mg of sacubitril and 103 mg of valsartan. The usual dosage information should be referred to from the prescribing information. The tablets are available in a pack of 180 tablets. It should be stored at a temperature between 15°C to 30°C. The manufacturer is MSN Laboratories Private Limited in Telangana, India, and the distributor is Novadoz Pharmaceuticals LLC in Piscataway, NJ. Remember to keep the medication out of reach of children and protect it from moisture. For further information, contact Novadoz Pharmaceuticals at 855-NOVADOZ.*

Each film-coated tablet contains 97 mg of sacubitril and 103 mg of valsartan. The usual dosage is indicated in the prescribing information. Store the tablets at room temperature between 59°F to 86°F and protect them from moisture. Keep the tablets out of reach of children. Manufactured by MSN Laboratories Private Limited in Telangana, India, and distributed by Novadoz Pharmaceuticals LLC in Piscataway, NJ. For more information, contact Novadoz Pharmaceuticals at 855- NOVADOZ.*

This text provides information on the geometric mean ratio and 90% confidence interval for the coadministration of various drugs, including Furosemide, Warfarin, Digoxin, Carvedilol, Levonorgestrel, Ethinyl estradiol, Amlodipine, HeTZ, Metformin, Atorvastatin, Sildenafil, and a relative change compared to the reference drug.*

This is a detailed evaluation of the Time to First Occurrence of CV Death or Heart Failure Hospitalizations in the PARADIGM-HF study, comparing the outcomes between Sacubitril and Valsartan versus Enalapril. The data includes hazard ratios, confidence intervals, and the number of patients at risk over specified periods since randomization. The figures presented in the text show significant differences in the incidence of CV death and heart failure hospitalizations between the two treatments.*

This is statistical data showing the percentage breakdown of different subgroups based on various factors such as age, gender, weight, race, region, NYHA class, estimated GFR, diabetes, systolic blood pressure, ejection fraction, atrial fibrillation, NT-proBNP, hypertension, and prior use of different medications in a study population. The data also includes the usage percentages of Sacubitril and Valsartan compared to Enalapril and their corresponding Hazard Ratio values.*